Multiple Myeloma

• 

  Subject Areas on Research

  • "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 
  • 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. 
  • A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. 
  • A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. 
  • A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. 
  • A Qualitative Study of the Experiences of Living With Multiple Myeloma. 
  • A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. 
  • A cross-sectional observational study of health-related quality of life in adults with multiple myeloma. 
  • A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. 
  • A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. 
  • A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. 
  • A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. 
  • A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. 
  • Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. 
  • Age as a prognostic factor in multiple myeloma. 
  • Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma. 
  • American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. 
  • An approach to monoclonal gammopathies in the elderly. 
  • Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. 
  • Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. 
  • Antinuclear antibodies and nuclear antigens in NZB myeloma ascitic fluids. 
  • Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model. 
  • Association between Kidney Function, Proteinuria and the Risk of Multiple Myeloma: A Population-Based Retrospective Cohort Study in South Korea. 
  • Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. 
  • Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma. 
  • Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. 
  • Associations between Alcohol Consumption Patterns and Risk of Multiple Myeloma: A Nationwide Cohort Study in South Korea. 
  • Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. 
  • Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. 
  • Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. 
  • Beyond Mirels: Factors Influencing Surgical Outcome of Metastasis to the Extremities in the Modern Era. 
  • Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. 
  • CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall. 
  • Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. 
  • Cases from the Osler medical service at Johns Hopkins University. 
  • Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. 
  • Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. 
  • Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical characteristics and outcomes in biclonal gammopathies. 
  • Clinical characteristics of testicular extramedullary involvement in multiple myeloma. 
  • Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. 
  • Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. 
  • Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. 
  • Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual. 
  • Connect MM Registry as a national reference for United States multiple myeloma patients. 
  • Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. 
  • Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. 
  • Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. 
  • Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. 
  • Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. 
  • Cytologic findings in vitreous fluids. Analysis of 74 specimens. 
  • Daratumumab Use Prior to Kidney Transplant and T Cell-Mediated Rejection: A Case Report. 
  • Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. 
  • Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature. 
  • Dielectrophoresis and electrorotation of neurospora slime and murine myeloma cells. 
  • Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy. 
  • Dysarthria and dysphagia from light chain amyloidosis. 
  • Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. 
  • Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. 
  • Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry. 
  • Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. 
  • Effects of age on responses to treatment and survival of patients with multiple myeloma. 
  • Effects of socioeconomic and clinical factors on survival in multiple myeloma. 
  • Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. 
  • Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. 
  • Erythrophagocytosis in a cyclin D1 positive plasma cell myeloma with near-tetraploid karyotypic abnormalities and cryptic MYC/IGH fusion. 
  • Evaluation and appraisal of randomized controlled trials in myeloma. 
  • Evaluation of hyperviscosity in monoclonal gammopathies. 
  • Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis. 
  • Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients. 
  • Evolving role of FDG PET/CT in multiple myeloma imaging and management. 
  • Expanding anti-CD38 immunotherapy for lymphoid malignancies. 
  • Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma. 
  • Familial aggregation of multiple myeloma and central nervous system diseases. 
  • Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation. 
  • Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. 
  • Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. 
  • Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. 
  • Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma. 
  • Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. 
  • Glucose metabolism as a target of histone deacetylase inhibitors. 
  • Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice. 
  • Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. 
  • Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). 
  • Hexamethylmelamine and prednisone in the treatment of refractory multiple myeloma. 
  • High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. 
  • High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. 
  • High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. 
  • Highlights from the 46 th annual meeting of the American Society of Hematology. 
  • Hospital versus random digit dialing controls in the elderly. Observations from two case-control studies. 
  • How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. 
  • Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. 
  • Hyperviscosity syndrome in association with kappa light chain myeloma. 
  • IRF4 addiction in multiple myeloma. 
  • Idiotypic cross-reaction between MRL autoantibodies and a BALB/c myeloma. 
  • IgG-lambda plasma cell myeloma with cytoplasmic azurophilic inclusion bodies. 
  • Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. 
  • Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. 
  • In vitro kinetics of immunoglobulin synthesis and secretion by nonsecretory human myeloma cells. 
  • Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. 
  • Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma. 
  • Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. 
  • Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. 
  • Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States. 
  • Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. 
  • Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. 
  • International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. 
  • International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. 
  • Intranuclear inclusions in Bence Jones lambda plasma cell myeloma. 
  • Is autologous stem cell transplantation still relevant for multiple myeloma? 
  • Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. 
  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. 
  • Lenalidomide after stem-cell transplantation for multiple myeloma. 
  • Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. 
  • Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. 
  • MR imaging and PET/CT in diagnosis and management of multiple myeloma. 
  • Managing the complications of plasma cell myeloma. 
  • Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. 
  • Monoclonal gammopathies and aging. 
  • Mortality among autoworkers manufacturing electronics in Huntsville, Alabama. 
  • Multimorbidity in patients with monoclonal gammopathy of undetermined significance. 
  • Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. 
  • Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Multiple myeloma and family history of cancer. A case-control study. 
  • Multiple myeloma in the elderly. 
  • Multiple myeloma in the elderly. 
  • Multiple myeloma in the very old: an IASIA conference report. 
  • Multiple myeloma, version 1.2013. 
  • Multiple myeloma-associated amyloidosis and giant cell arteritis. 
  • Multiple myeloma. 
  • Multiple myeloma. Clinical practice guidelines in oncology. 
  • Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens. 
  • Myeloma light chains are ligands for cubilin (gp280). 
  • Myelomatous meningeal infiltration detected by magnetic resonance imaging. 
  • Myelomatous pleural effusion: clinical course and immunologic characterization of the pleural fluid cells. 
  • NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. 
  • NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. 
  • NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. 
  • NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. 
  • NCCN clinical practice guidelines in oncology: multiple myeloma. 
  • Neoplastic plasma cells with azurophilic crystalline inclusions mimicking promyelocytes. 
  • Neurological disorders with abnormalities of immunoglobulin metabolism. 
  • Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern. 
  • Ocular manifestations of multiple myeloma, Waldenström's macroglobulinemia and benign monoclonal gammopathy. 
  • Older patients with myeloma derive similar benefit from autologous transplantation. 
  • Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. 
  • Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. 
  • Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. 
  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. 
  • Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. 
  • PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. 
  • PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo. 
  • Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade. 
  • Panobinostat for the management of multiple myeloma. 
  • Pathway-based identification of SNPs predictive of survival. 
  • Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study. 
  • Performance evaluation of the Helena V8 capillary electrophoresis system. 
  • Pericarditis mediated by respiratory syncytial virus in a hematopoietic stem cell transplant patient. 
  • Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. 
  • Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma. 
  • Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. 
  • Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. 
  • Phase II evaluation of chlorozotocin in refractory multiple myeloma. 
  • Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. 
  • Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. 
  • Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy. 
  • Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. 
  • Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. 
  • Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. 
  • Pleural amyloidosis. 
  • Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. 
  • Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease. 
  • Prospective Multireader Evaluation of Photon-counting CT for Multiple Myeloma Screening. 
  • Pseudo-Gaucher cells in multiple myeloma. 
  • Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma. 
  • Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study. 
  • Race and myeloma survival. 
  • Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. 
  • Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. 
  • Recognition of early mortality in multiple myeloma by a prediction matrix. 
  • Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma. 
  • Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. 
  • Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies. 
  • Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. 
  • Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. 
  • Role of immune stimulation in the etiology of multiple myeloma: a case control study. 
  • Role of urine and serum protein electrophoresis in evaluation of nephrotic-range proteinuria. 
  • Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes. 
  • Secondary osteoporosis. Diagnostic considerations. 
  • Selinexor for the treatment of patients with previously treated multiple myeloma. 
  • Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. 
  • Shrinkage-based diagonal discriminant analysis and its applications in high-dimensional data. 
  • Socioeconomic status and risk of multiple myeloma. 
  • Stem cell transplantation for multiple myeloma. 
  • Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma. 
  • Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma. 
  • Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. 
  • THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. 
  • Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. 
  • Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. 
  • The challenges of checkpoint inhibition in the treatment of multiple myeloma. 
  • The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. 
  • The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. 
  • The kinetics of immunoglobulin synthesis by pokeweed mitogen stimulated peripheral blood lymphocytes in multiple myeloma. 
  • The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. 
  • The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. 
  • The uncertainty principle and industry-sponsored research. 
  • The value of looking. Multiple myeloma discovered by an unusual finding in Gram-stained spinal fluid. 
  • Therapy of myeloma. 
  • Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. 
  • Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. 
  • Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. 
  • Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry. 
  • Treatment of hostile midline back wounds: an extreme approach. 
  • Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. 
  • Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry. 
  • Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. 
  • Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. 
  • Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. 
  • Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism. 
  • Using the bioconductor GeneAnswers package to interpret gene lists. 
  • Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. 
  • Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group Trial. 
  • What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. 
  • Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. 
  • rHuEPO and improved treatment outcomes: potential modes of action. 
• 

  Keywords of People

  • Choi, Taewoong, Assistant Professor of Medicine, Duke Cancer Institute
  • Costa, Cristiana A., Assistant Professor of Medicine, Duke Cancer Institute
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • Nikiforov, Mikhail A., Professor of Pathology, Biomedical Engineering
  • Young, Ken H, Professor of Pathology, Pathology